Regeneron Pharma (REGN) PT Raised to $494 at BMO Capital

BMO Capital analyst Jim Birchenough lifted his price target on Regeneron Pharma (NASDAQ: REGN) to $494.00 (from $381.00) following Praluent approval but maintained his Market Perform rating, saying he expects moderate uptake.

Birchenough commented, "We are maintaining our Market Perform rating on the shares of REGN following PRALUENT approval. While opportunity for more optimized LDL management is significant, we expect tentative PRALUENT adoption pending visibility on outcomes data. The shares are reasonably valued in our opinion."

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $541.85 yesterday.

You May Also Be Interested In

• QuantumScape (QS) PT Lowered to $6 at Truist Securities
• TD Cowen Resumes EQT Corp. (EQT) at Hold
• Synovus Financial (SNV) PT Lowered to $42 at Piper Sandler